{"entity":{"id":"eris-biotech","kind":"company","name":"Eris Biotech","aka":[],"tldr":"Eris Biotech is making small-molecule pills that release the brakes on the immune system inside tumours, starting with mesothelioma.","summary":"Eris Biotech develops small molecules that inhibit immune suppression in the tumour microenvironment so that the patient's immune system attacks solid tumours more aggressively, an oral alternative to antibody checkpoint inhibitors. Its first indication is mesothelioma, with a portfolio the company says extends to a range of solid tumours. The Utah company is preclinical with a very small team; no sourced financing rounds are recorded.","asOf":"2026-09-10","links":[{"label":"Y Combinator profile","url":"https://www.ycombinator.com/companies/eris-biotech"},{"label":"Official website","url":"https://www.erisbio.com"}],"tags":["yc"],"related":[],"cancers":["mesothelioma"],"sections":["immunotherapy"],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Lehi, UT","country":"US","companyType":"biotech","website":"https://www.erisbio.com","stage":"startup","ycBatch":"W24","investors":["y-combinator"],"funding":[]},"route":"/companies/eris-biotech/","neighbours":{"cancer":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"company":[{"id":"y-combinator","kind":"company","name":"Y Combinator","route":"/companies/y-combinator/"}]}}